<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00317954</url>
  </required_header>
  <id_info>
    <org_study_id>2612-2233</org_study_id>
    <nct_id>NCT00317954</nct_id>
  </id_info>
  <brief_title>Spironolactone in Diabetic Nephropathy</brief_title>
  <official_title>Spironolactone in Diabetic Nephropathy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Steno Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Steno Diabetes Center</source>
  <brief_summary>
    <textblock>
      The aim of the study was to evaluate the renoprotective effect (i.e. albuminuria- and
      bloodpressure lowering effect) of spironolactone 25 mg o.d. in type 1 and type 2 diabetic
      patients with albuminuria despite recommended antihypertensive treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2003</start_date>
  <completion_date>July 2005</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in albuminuria</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in blood pressure</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in glomerular filtration rate</measure>
  </secondary_outcome>
  <enrollment>48</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Spironolactone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetes Mellitus

          -  Diabetic Nephropathy

          -  Glomerular filtration rate &gt; 30 ml/min/1.73 m2

          -  Blood pressure &gt; 130/80 mm Hg

        Exclusion Criteria:

          -  Child bearing potential

          -  Plasma-potassium &gt;4.5 mmol/l

          -  Breastfeeding

          -  Abuse of alcohol or drugs

          -  Non-diabetic kidney disease
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hans-Henrik Parving, MD,DMSc,Prof</last_name>
    <role>Study Chair</role>
    <affiliation>Steno Diabetes Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Katrine J Schjoedt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Steno Diabetes Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Steno Diabetes Center</name>
      <address>
        <city>Gentofte</city>
        <zip>2820</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <results_reference>
    <citation>Schjoedt KJ, Rossing K, Juhl TR, Boomsma F, Rossing P, Tarnow L, Parving HH. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005 Dec;68(6):2829-36.</citation>
    <PMID>16316360</PMID>
  </results_reference>
  <results_reference>
    <citation>Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving HH. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care. 2005 Sep;28(9):2106-12.</citation>
    <PMID>16123474</PMID>
  </results_reference>
  <verification_date>August 2005</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 21, 2006</study_first_submitted>
  <study_first_submitted_qc>April 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2006</study_first_posted>
  <last_update_submitted>April 21, 2006</last_update_submitted>
  <last_update_submitted_qc>April 21, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2006</last_update_posted>
  <keyword>Diabetic nephropathy</keyword>
  <keyword>Spironolactone</keyword>
  <keyword>Aldosterone antagonism</keyword>
  <keyword>Renoprotection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spironolactone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

